JPH11239465A - Food product for healthy persons to increase their moving ability - Google Patents

Food product for healthy persons to increase their moving ability

Info

Publication number
JPH11239465A
JPH11239465A JP10168132A JP16813298A JPH11239465A JP H11239465 A JPH11239465 A JP H11239465A JP 10168132 A JP10168132 A JP 10168132A JP 16813298 A JP16813298 A JP 16813298A JP H11239465 A JPH11239465 A JP H11239465A
Authority
JP
Japan
Prior art keywords
fatty acids
fatty acid
acid
polyunsaturated fatty
fish oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10168132A
Other languages
Japanese (ja)
Inventor
Hideji Nakajima
秀司 中島
Tetsuya Murakami
哲也 村上
Yoichi Sekiguchi
洋一 関口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissui Corp
Original Assignee
Nippon Suisan Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Suisan Kaisha Ltd filed Critical Nippon Suisan Kaisha Ltd
Priority to JP10168132A priority Critical patent/JPH11239465A/en
Publication of JPH11239465A publication Critical patent/JPH11239465A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide a food product that can increase the moving ability of healthy persons such as sport lovers, persons who want to play sport, and persons who aims increasing their endurance. SOLUTION: This food product contains n-3 highly unsaturated fatty acids and has the performance to increase the maximum oxygen intake and the anaerobic threshold by at least 3%. The n-3 highly unsaturated fatty acids means n-3 highly unsaturated fatty acids and/or their derivatives, preferably eicosapentaenoic acid and/or docosa-hexaenoic acid. The n-3 highly unsaturated fatty acid is preferably in the form of naturally occurring triglyceride, preferably in the form of fish oil. This food products are liquid or solid and both of them are capsulated.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【産業の属する技術分野】本発明は、スポーツ愛好家、
スポーツをしたい人、持久力の向上を目指す人などの健
常人のための運動能力を高める食品に関する。また、本
発明は、有酸素能力を高め、長距離走の競技力向上の補
助的な手段として有効である運動能力向上栄養食品に関
する。
TECHNICAL FIELD The present invention relates to a sports enthusiast,
The present invention relates to foods that enhance athletic ability for healthy people such as those who want to play sports and those who aim to improve their endurance. The present invention also relates to a nutritional food with enhanced athletic ability, which enhances aerobic ability and is effective as an auxiliary means for enhancing competitiveness in long-distance running.

【0002】[0002]

【従来の技術】予防医学の見地から日本人の魚介類摂取
度別にみた死因別死亡率について、1965年から19
82年の17年間にかけて約27万人を対象に調査した
結果〔平山、中外医薬45(3),45-50,1992〕
によると、魚介類の毎日摂取者は、多くの食品のなかで
もとくに低い総死亡率を示し、長寿に直結すること、死
因別では、脳血管疾患、心臓病、高血圧、肝硬変、アル
ツハイマー病、パーキンソン病、癌(胃癌、肝臓癌、子
宮癌など)がとくに低率となることを確認している。欧
米での最大の死因は心臓病であるが、日本では癌であ
る。欧米の心臓病の中心は心筋梗塞など虚血性心疾患で
あるが、日本では米国の約5分の1程度である。戸嶋
ら、家森らも世界各国の食生活を比較し、米、魚、大
豆、野菜などが主体の日本の食生活が心臓病を防いだ
り、長寿食であることを報告している。
2. Description of the Related Art From the viewpoint of preventive medicine, the mortality rate by cause of death by Japanese fish and shellfish intake from 1965 to 19
Results of a survey of approximately 270,000 people over the 17 years of 1982 [Hirayama, Chugai Pharmaceutical 45 (3), 45-50, 1992]
According to the report, daily consumers of seafood have a particularly low overall mortality rate among many foods and are directly linked to longevity.By cause of death, cerebrovascular disease, heart disease, high blood pressure, liver cirrhosis, Alzheimer's disease, Parkinson's Disease and cancer (stomach cancer, liver cancer, uterine cancer, etc.) have been confirmed to be particularly low rates. The leading cause of death in Europe and the United States is heart disease, but in Japan it is cancer. The heart of heart disease in Europe and the United States is ischemic heart disease such as myocardial infarction, but in Japan it is about one-fifth of that in the United States. Toshima et al. And Iemori et al. Also compared dietary habits around the world and reported that Japanese dietary habits mainly consisting of rice, fish, soybeans, and vegetables prevent heart disease and are long-lived.

【0003】栄養学の立場から魚介類を評価すると、日
本人が摂取する蛋白質(39%)、脂質(10.1
%)、カルシウム(12.8%)、鉄分(13%)、ビ
タミンB 2(14.3%)の重要な供給源となってい
る。水産物由来の蛋白質は、一般にアミノ酸バランスに
優れ、また、エキス中には含硫アミノ酸のタウリンも豊
富に含まれている。タウリンは蛋白質に組み込まない遊
離の状態で存在しているが、健康人には、体重1kg当
たり約1g含まれている。タウリンの生理作用として
は、循環器系に対する作用、肝臓機能に対する作用、神
経系に対する作用などが知られている。さらに、運動時
におけるタウリンの挙動も注目されている。例えば、縄
跳び運動時の血清遊離アミノ酸の変化を追いかけた研究
では、タウリンの変動が大きいことが確認され、運動時
に上昇傾向を、終了時に減少傾向を示すことが報告され
ている〔本多、東医大誌50(1),3-10,199
2〕。また、ラットにランニング運動をさせたときのタ
ウリンの挙動を尿中排泄量から測定した結果、運動群で
は排泄量が少なくなることから、運動時に含硫アミノ酸
の体内での利用が亢進していると推察されている〔東條
ほか、必須アミノ酸研究134,18-20,199
2〕。
[0003] When evaluating seafood from a nutritional standpoint,
Protein (39%) and lipid (10.1)
%), Calcium (12.8%), iron (13%),
Tamin B Two(14.3%) is an important source
You. Seafood-derived proteins generally have an amino acid balance
Excellent, and rich in taurine, a sulfur-containing amino acid, in the extract
Included in wealth. Taurine is not incorporated into proteins
It exists in a separated state, but for healthy people,
Approximately 1 g is contained. As a physiological effect of taurine
Has effects on the circulatory system, effects on liver function,
The effects on the transsystem are known. In addition, during exercise
Is also attracting attention. For example, a rope
A study tracking changes in serum free amino acids during jumping
It was confirmed that the fluctuation of taurine was large,
Reported an upward trend and a downward trend at the end.
[Honda, Higashi Medical Journal50(1), 3-10, 199
2]. In addition, when running rats,
As a result of measuring urinary behavior from urinary excretion,
Is a sulfur-containing amino acid during exercise
It is presumed that the use in the body is increasing [Tojo
Other essential amino acid research134, 18-20, 199
2].

【0004】ペプチドは、蛋白質を酵素などで加水分解
したときに得られるアミノ酸が結合したものであるが、
水産蛋白質由来のペプチドには、南極オキアミ由来のト
リペプチドの「Lue−Lys−Tyr」やイワシペプ
チドなどで血圧低下作用が報告されている。非常に安全
性が高く長期間摂取できる機能性素材としての利用が期
待される。
[0004] Peptides are those in which amino acids obtained when a protein is hydrolyzed with an enzyme or the like are bound.
Regarding peptides derived from marine proteins, a tripeptide “Lue-Lys-Tyr” derived from Antarctic krill and a sardine peptide have been reported to have a blood pressure lowering effect. It is very safe and expected to be used as a functional material that can be taken for a long time.

【0005】脂質は、エネルギー源として必要なだけで
なく身体の機能を維持するために必要な必須脂肪酸や脂
溶性物質の供給のために一定量を摂取することが必要と
される。動物、植物、魚類には異なった種類の脂肪酸が
含まれているので、これらをバランスよく摂取すること
が推奨されるが、バランス比については日本人の栄養摂
取量の4:5:1程度となっていることからこれが一つ
の目安とされている。脂質を構成している脂肪酸には、
飽和脂肪酸、一価不飽和脂肪酸、多価不飽和脂肪酸があ
るが、これらの脂肪酸の望ましい摂取比率はおおむね
1:1.5:1とされている。多価不飽和脂肪酸には必
須脂肪酸が含まれていて発育成長と健康維持に必要であ
る。必要量としては総エネルギーの3%くらいといわれ
ている。多価不飽和脂肪酸としては、植物の中に多いn
−6系のリノール酸が知られているが、最近、水産物に
多いn−3系のエイコサペンタエン酸(EPA)やドコ
サヘキサエン酸(DHA)の重要性が注目されている。
低温下でも固まりにくい物性を示し、生体内で多く存在
している膜組織などを柔軟に保つ作用が期待される。E
PA、DHAは背の青い魚(イワシ、アジ、マグロ、サ
ンマ、サバなど)に多く含まれている。
It is necessary to take a certain amount of lipids not only as an energy source but also for supplying essential fatty acids and fat-soluble substances necessary for maintaining body functions. Animals, plants, and fish contain different kinds of fatty acids, so it is recommended that they be ingested in a balanced manner. However, the balance ratio is about 4: 5: 1 of the nutritional intake of Japanese. Therefore, this is one guideline. Fatty acids that make up lipids include:
There are saturated fatty acids, monounsaturated fatty acids, and polyunsaturated fatty acids, and the desirable intake ratio of these fatty acids is generally set to 1: 1.5: 1. Polyunsaturated fatty acids contain essential fatty acids and are necessary for developmental growth and health maintenance. It is said that the required amount is about 3% of the total energy. Polyunsaturated fatty acids include n which is high in plants.
Although -6-type linoleic acid is known, the importance of n-3-type eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are often present in marine products, has attracted attention.
It exhibits physical properties that do not easily solidify even at low temperatures, and is expected to have the effect of keeping the membrane tissues and the like that are often present in the living body flexible. E
PA and DHA are abundant in blue fish (sardines, horse mackerel, tuna, saury, mackerel, etc.).

【0006】これらの魚油成分が注目されたのは、エキ
スモー人の食生活と疾病に関する疫学調査で、心臓や動
脈などの循環器系疾患に及ぼす魚食の効果が明らかにさ
れて以来である。その後、これらの脂肪酸の生理作用に
ついて、精力的に研究が進められ、EPAでは、慢性動
脈閉塞症の治療薬として利用されるに至っている。EP
AやDHAの生理作用としては、血中の中性脂質、総コ
レステロールの減少、HDLコレステロールの増加、血
小板凝集能の低下、血液粘度の低下、赤血球変形能の増
加などが知られている。現象的には、血液がサラサラし
て固まりにくくなるということである。また、DHAに
ついては、脳の細胞膜組織の中に多量に存在することか
ら、学習機能など神経組織に関係する機能に影響するこ
とが期待され盛んに研究が進められている。一方、順天
堂大の沢木らは、リレハンメル冬季オリンピックで好成
績をおさめたノルウェーの選手が栄養補助食品としてD
HAやEPAを利用していることに注目し、陸上長距離
選手を対象にDHA、EPAの摂取がトレーニング効果
に及ぼす影響について研究した。その結果、彼らの競技
成績に大きな差を認め、DHA、EPAの摂取が毛細血
管への酸素運搬能力の向上を引き起こすことを推察して
いる。今後、これら脂肪酸の運動機能に及ぼす影響に関
する研究がますます活発化するものと思われるが、研究
成果によって裏付けされた具体的な実用化技術の開発が
待たれるところである。
Attention has been paid to these fish oil components since the effects of fish diet on cardiovascular diseases such as hearts and arteries have been clarified in epidemiological studies on diets and diseases of Exmo people. Since then, the physiologic effects of these fatty acids have been energetically studied, and EPA has been used as a therapeutic agent for chronic arterial occlusion. EP
Known physiological actions of A and DHA include a decrease in neutral lipids and total cholesterol in blood, an increase in HDL cholesterol, a decrease in platelet aggregation ability, a decrease in blood viscosity, and an increase in erythrocyte deformability. The phenomena is that the blood is smooth and hard to clot. In addition, DHA is abundantly present in the cell membrane tissue of the brain, and is expected to affect functions related to nerve tissue such as learning functions, and has been actively studied. On the other hand, Sawaki et al. Of Juntendo University reported that Norwegian athletes who had good results at the Lillehammer Winter Olympics
Focusing on the use of HA and EPA, we studied the effects of ingestion of DHA and EPA on training effects for long-distance athletes on land. As a result, a large difference was observed in their athletic performance, and it was speculated that ingestion of DHA and EPA caused an improvement in the ability to transport oxygen to capillaries. In the future, studies on the effects of these fatty acids on motor function are expected to become more and more active, but the development of concrete practical technology supported by the research results is awaited.

【0007】[0007]

【発明が解決しようとする課題】本発明の目的は、スポ
ーツ愛好家、スポーツをしたい人、持久力の向上を目指
す人などの健常人のための運動能力を高める食品を提供
することにある。また、本発明の目的は、有酸素能力を
高め、長距離走の競技力向上の補助的な手段として有効
である運動能力向上栄養食品を提供することにある。
SUMMARY OF THE INVENTION It is an object of the present invention to provide a foodstuff that enhances athletic performance for healthy people such as sports enthusiasts, those who want to play sports, and those who aim to improve their endurance. Another object of the present invention is to provide an athletic ability-enhancing nutritional food which enhances aerobic ability and is effective as a supplementary means for improving athletic ability for long-distance running.

【0008】[0008]

【課題を解決するための手段】本発明者らは、持久力向
上のための補助的な手段としてこれまでにビタミンE、
Cやスクアレン(Squalene:深海鮫の肝油主成
分)などの服用を試みてきた。その効果について実験室
内での運動能力テスト、及び生化学的な実験結果から、
ビタミンE、Cでは両者が相乗的に働くことで運動能力
の向上に対する有効性を見いだし、またスクアレンも同
様に鍛練された長距離選手の有酸素能力に有効であると
いう知見を得た。それらの成果を踏まえて、本発明は、
最近、ミクロ循環での酸素供給を高め、有酸素運動能力
を高める効果がある食品のひとつとされているn−3脂
肪酸に注目することとした。魚油に含まれているn−3
脂肪酸の有効性に関する科学的証明は少なく、競技力の
高い長距離選手における事例的な研究もほとんどなされ
ていない。
Means for Solving the Problems The present inventors have previously proposed vitamin E, as an auxiliary means for improving endurance.
C and Squalene (a major component of deep sea shark liver oil) have been tried. From the athletic ability test in the laboratory about the effect and the biochemical experiment result,
Vitamin E and C found that they work synergistically to improve athletic performance, and also found that squalene was also effective for aerobic abilities of trained long-distance athletes. Based on these results, the present invention
Recently, attention has been paid to n-3 fatty acids, which are considered to be one of foods that have an effect of increasing oxygen supply in microcirculation and enhancing aerobic exercise performance. N-3 contained in fish oil
There is little scientific evidence on the effectiveness of fatty acids, and little case study in highly competitive long-distance athletes.

【0009】最大酸素摂取量は、最大限の努力で5分間
程度続けられる運動をするときに、その人が体内に取り
込む ことのできる酸素量であり、高いほど良い。被験
者以外の人間も含んだ17人の最大酸素摂取量を測定し
た。結果を表1に示した。最大酸素摂取量は平均すると
70.7±4.1ml/kg/分である。人類の限界が8
3〜85ml/kg/分であると言われており、平地での
トレーニング、あるいは何らかの処置に対する応答につ
いては、数値的には通常人よりも高レベルな被験者にお
いては、摂取により3〜5%の変化があれば十分に意味
のある改善であると考えられる。
[0009] The maximum oxygen intake is the amount of oxygen that the person can take into the body when exercising for about 5 minutes with the maximum effort, and the higher the better, the better. The maximum oxygen uptake of 17 persons including humans other than the subjects was measured. The results are shown in Table 1. Maximal oxygen uptake averages 70.7 ± 4.1 ml / kg / min. Eight human limitations
It is said to be 3 to 85 ml / kg / min, and the response to training on level ground or to any treatment is 3-5% due to ingestion in subjects numerically higher than normal. Any change is considered a sufficiently significant improvement.

【0010】[0010]

【表1】 [Table 1]

【0011】本発明は、n−3系高度不飽和脂肪酸を含
有し、最大酸素摂取量及び無気的閾値を少なくとも3%
向上する機能を有することを特徴とする健常人が運動能
力を高める食品を要旨としている。上記のn−3系高度
不飽和脂肪酸が、n−3高度不飽和脂肪酸または/およ
びその誘導体であり、該n−3高度不飽和脂肪酸は、好
ましくはエイコサペンタエン酸および/またはドコサヘ
キサエン酸であり、したがって本発明は、n−3高度不
飽和脂肪酸、好ましくはエイコサペンタエン酸および/
またはドコサヘキサエン酸、または/およびその誘導体
を含有し、最大酸素摂取量及び無気的閾値を少なくとも
3%向上する機能を有することを特徴とする健常人が運
動能力を高める食品を要旨としている。上記のn−3系
高度不飽和脂肪酸の好ましい形態は、天然のトリグリセ
ライドの形態、好ましくは魚油である。本発明の食品
は、液状または固形であり、いずれの場合もカプセルに
入っている形態であることができる。
The present invention comprises n-3 polyunsaturated fatty acids and has a maximum oxygen uptake and an anaerobic threshold of at least 3%.
The gist is a food that enhances athletic ability by a healthy person, which is characterized by having an improving function. The n-3 polyunsaturated fatty acid is an n-3 polyunsaturated fatty acid or / and a derivative thereof, and the n-3 polyunsaturated fatty acid is preferably eicosapentaenoic acid and / or docosahexaenoic acid; Thus, the present invention provides n-3 highly unsaturated fatty acids, preferably eicosapentaenoic acid and / or
Alternatively, the gist of the present invention is a food containing docosahexaenoic acid, or / and a derivative thereof, and having a function of improving the maximum oxygen intake and the anaerobic threshold value by at least 3%, which enhances the exercise ability of a healthy person. The preferred form of the above n-3 polyunsaturated fatty acids is the form of natural triglycerides, preferably fish oil. The food of the present invention may be in the form of a liquid or a solid, in each case in a capsule.

【0012】[0012]

【発明の実施の形態】本発明において、n−3系高度不
飽和脂肪酸は、n−3系高度不飽和脂肪酸または/およ
びその誘導体を使用する。より具体的に例示すれば、精
製魚油、エイコサペンタエン酸およびまたはドコサヘキ
サエン酸の濃度を高めた精製魚油、構成脂肪酸のうちn
−3系高度不飽和脂肪酸が60%以上残りは中鎖脂肪酸
であるような吸収性を高めた油脂組成物などのn−3系
高度不飽和脂肪酸を主成分とする油脂組成物を使用する
ことができる。上記精製魚油は、イワシ油、マグロ油、
サンマ油、ニシン油、サバ油、タラ肝油、イカ油、メン
ヘーデン油などを脱酸、脱色、脱臭、脱ガム、脱ロウな
どの精製方法で処理したものである。EPA、DHAの
合計含量が20重量%以上の精製魚油、コレステロール
0.1%以下、EPA,DHA高含有量の無味無臭の魚
油が例示される。
BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, as the n-3 polyunsaturated fatty acid, an n-3 polyunsaturated fatty acid or / and a derivative thereof is used. More specifically, for example, refined fish oil, refined fish oil having an increased concentration of eicosapentaenoic acid and / or docosahexaenoic acid, and n
Use of an oil / fat composition containing an n-3 type highly unsaturated fatty acid as a main component, such as an oil / fat composition having enhanced absorbency such that the remainder of the -3 type highly unsaturated fatty acid is 60% or more of the medium chain fatty acid. Can be. The purified fish oil is sardine oil, tuna oil,
Saury oil, herring oil, mackerel oil, cod liver oil, squid oil, menhaden oil, etc. are processed by a purification method such as deacidification, decolorization, deodorization, degumming, and dewaxing. Examples include refined fish oil having a total content of EPA and DHA of 20% by weight or more, and odorless and odorless fish oil having a high EPA and DHA content of 0.1% or less.

【0013】魚油の精製は、原料から採取した遊離脂肪
酸、臭気成分、着色成分などが含まれている粗原油から
これらを除去するために行うが、精製法としてはアルカ
リ精製法、蒸気吹込法、吸着法などがあり、任意に組み
合わせて行われる。アルカリ精製法は脱酸法ともいい、
粗製油に水酸化ナトリウムを加えて魚油中の遊離脂肪酸
をフーツ(石鹸、foots)にすると共に、フーツに
不純物を吸着または溶解させ、これを除去して粗製油を
精製する方法である。蒸気吹込法は、精製油を減圧下で
150℃前後に加熱し、これに水蒸気を吹き込んで臭気
成分を除去する方法である。また吸着法は、活性炭、酸
性白土などの吸着剤を用いて粗製油中の着色成分や臭気
成分を吸着・除去する方法である。
[0013] Fish oil is refined to remove it from crude crude oil containing free fatty acids, odor components, coloring components, etc. collected from the raw material. The refining methods include alkali refining, steam blowing, There are adsorption methods and the like, which are performed in any combination. The alkali purification method is also called a deoxidation method,
In this method, sodium hydroxide is added to the crude oil to convert the free fatty acids in the fish oil into foots (soaps), and impurities are adsorbed or dissolved in the foots to remove the impurities, thereby purifying the crude oil. The steam blowing method is a method in which a refined oil is heated to about 150 ° C. under reduced pressure, and steam is blown into this to remove odor components. The adsorption method is a method of adsorbing and removing coloring components and odor components in crude oil using an adsorbent such as activated carbon and acid clay.

【0014】これらの公知精製方法を駆使することによ
り魚油を無味無臭まで精製し、さらに魚油からコレステ
ロールを実質的に除去する。本発明の実施例においては
魚油をコレステロール0.1%以下、EPA,DHA高
含有量の無味無臭の魚油に調製して使用する。本発明の
実施例において使用する無味無臭の魚油に含まれるEP
A,DHA等の脂肪酸はトリグリセリドの形態で存在し
ている。EPA,DHAの含有量は、例えば、EPA1
8%、DHA8〜12%のもの、EPA28%、DHA
12%のもの、EPA5〜8%、DHA22%のものの
ように、使用用途等によって任意に変化させることがで
きる。いずれのものもコレステロールの含有量は0.1
%以下である。
By making full use of these known purification methods, fish oil is refined to tasteless and odorless, and cholesterol is substantially removed from fish oil. In the embodiment of the present invention, fish oil is prepared and used as a tasteless and odorless fish oil having a cholesterol of 0.1% or less and a high content of EPA and DHA. EP contained in tasteless and odorless fish oil used in embodiments of the present invention
Fatty acids such as A and DHA exist in the form of triglycerides. The content of EPA and DHA is, for example, EPA1
8%, DHA 8-12%, EPA 28%, DHA
It can be arbitrarily changed depending on the intended use, such as 12%, EPA 5 to 8%, and DHA 22%. All of them have a cholesterol content of 0.1
% Or less.

【0015】本発明の健常人が運動能力を高める食品
は、スポーツ愛好家、スポーツをしたい人、持久力の向
上を目指す人などの健常人が運動能力を高める食品とし
て毎日の栄養補給として食する。毎日栄養補給を続ける
と健常人は有酸素能力が高まり運動能力が高まる。
The food of the present invention that enhances the athletic ability of healthy people is eaten by a healthy person such as a sports enthusiast, a person who wants to play sports, or a person who aims to improve endurance as daily nutritional supplement as a food that enhances athletic ability. . Maintaining healthy daily nutrition increases the aerobic and exercise capacity of healthy individuals.

【0016】本発明の健常人が運動能力を高める食品に
おいては、必須成分であるn−3系高度不飽和脂肪酸の
他に、任意的成分として、通常食品に添加されるビタミ
ン類、炭水化物色素、香料など適宜配合することができ
る。また、必要に応じて乳化剤を添加することもでき
る。乳化剤としてはグリセリン脂肪酸エステル、しょ糖
脂肪酸エステル、ソルビタン脂肪酸エステル、大豆リン
脂質、プロピレングリコール脂肪酸エステルが用いら
れ、これらは単独又は組合せて用いられる。食品は液状
または固形の任意の形態で食することができる。ゼラチ
ンなどで外包してカプセル化した軟カプセル剤として食
することができる。カプセルは、例えば、原料ゼラチン
に水を加えて溶解し、これに可塑剤(グリセリン、D−
ソルビトールなどを加えることにより調製したゼラチン
皮膜でつくられる。
[0016] In the food of the present invention for improving the exercise ability of healthy people, vitamins, carbohydrate pigments and the like, which are usually added to foods, are added as optional components in addition to the essential components of n-3 polyunsaturated fatty acids. Flavors and the like can be appropriately blended. Further, an emulsifier can be added as needed. Examples of the emulsifier include glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, soybean phospholipid, and propylene glycol fatty acid ester, and these may be used alone or in combination. The food can be eaten in any form, liquid or solid. It can be eaten as a soft capsule encapsulated by encapsulation with gelatin or the like. Capsules are dissolved, for example, by adding water to raw gelatin and adding a plasticizer (glycerin, D-
It is made of a gelatin film prepared by adding sorbitol and the like.

【0017】[0017]

【実施例】以下に本発明について具体的な実施例をもっ
て説明するが、本発明はこれらの実施例によって何ら制
限を受けるものではない。
EXAMPLES The present invention will be described below with reference to specific examples, but the present invention is not limited by these examples.

【0018】実施例1 本実施例は、n−3脂肪酸を被験者に実験的に一定期間
服用させ、実際の競技パフォーマンス(10,000
m)に与える影響を順天堂大学体力測定研究室の協力を
得ながら検討を行った。実験の方法として順天堂大学陸
上競技部の選手の2年間の10,000mの記録を基に
比較検討を行った。初年度と次年度の両年に実施したト
レーニングは年間トレーニング計画の中で、量、質とも
に同等の内容のもので、ほぼ同様の環境下で行われた。
検討された10,000mの記録は両年ともにほぼ同時
期に計測されたものを資料とした。初年度の1994年
にはn−3脂肪酸は服用せず、次年度の1995年は4
カ月間(7月〜10月末)に渡り、毎日、n−3脂肪酸
のカプセル6錠を被験者に朝3錠、夕3錠規則正しく服
用させ服用前後の記録に与えるn−3脂肪酸の影響を考
察した。
Example 1 In this example, a test subject was taken n-3 fatty acids experimentally for a certain period of time, and actual competition performance (10,000) was taken.
m) was investigated with the cooperation of Juntendo University Physical Fitness Laboratory. As a method of the experiment, a comparative study was conducted based on a two-year 10,000 m record of athletes of the Juntendo University Athletics Club. The training conducted in both the first year and the next year was conducted in almost the same environment in terms of quantity and quality in the annual training plan.
The 10,000m record considered was taken from data measured at about the same time in both years. In the first year of 1994, n-3 fatty acids were not taken, and in the next year, 1995
During the month (July to the end of October), subjects were given 6 tablets of n-3 fatty acids daily, 3 tablets in the morning and 3 evenings, and the effect of n-3 fatty acids on the pre- and post-recording was examined. .

【0019】2年間の順天堂大学陸上競技部の選手の1
0,000mの記録の変化を表2、表3に示した。n−
3脂肪酸を服用した1995年の10,000mの記録
の変化において、チーム全体では服用後の方が平均で−
51.0秒の短縮であった(表2,図1)。また、2年
間の平均記録の変化を比較すると、1994年の−5.
4秒(+0.3%)の短縮に比べて1995年ではさら
に45.6秒短縮し−51.0秒(+2.8%)という
有意な変化結果を示した(表4)。同一グループの2年
間の服用前後(1994年は1995年と同時期)の1
0,000mの記録の変化においても、n−3脂肪酸を
服用した1995年の方が1994年よりも平均で−1
4秒の短縮を示した(表5,図2)。このような10,
000mの記録の短縮の背景を考察する上で、2年間に
ほぼ同様のトレーニングを実施したことを前提とする
と、被験者の持久力能力に対してトレーニング効果に加
えて補助的に摂取したn−3脂肪酸の有効性が示唆され
た。n−3脂肪酸の有効性として、これまでに筋肉内毛
細血管の血流量の増加や、線維素溶解能と赤血球変形能
が高まることによる末梢の酸素供給などが報告されてい
る。これらはいずれも有酸素運動能力に関連する諸機能
の向上が期待される影響を考えられ、本実施例の被験者
にも同様の影響が現れていることが推察される。その結
果、n−3脂肪酸を服用した年としなかった年の10,
000mの記録の短縮に著しい差が現れたものと思われ
た。一般的にトレーニングの効果は専門的なトレーニン
グを開始後、初期ほど顕著に現れ、年月を経るほど効果
が低下すると言われている。また、競技レベル(記録)
の低い時期ほど記録の向上率も高いことも同様である。
この点からもハイレベルの現役アスリートを対象とした
本実験で見られた記録の向上は特異な変化と考えられ
る。以上のことからn−3脂肪酸を一定期間服用するこ
とが、有酸素能力を高め、長距離走の競技力向上の補助
的な手段として有効であることが示唆された。
One of the two-year athletes of Juntendo University Athletics Club
Tables 2 and 3 show the changes in the recording at 000 m. n-
In the record change of 10,000m in 1995 when three fatty acids were taken, the whole team took on average after taking-
This was a reduction of 51.0 seconds (Table 2, FIG. 1). Also, comparing the changes in the average records over the past two years, it is clear that the -5.
In 1995, compared with the reduction of 4 seconds (+ 0.3%), the time was further reduced by 45.6 seconds, showing a significant change result of −51.0 seconds (+ 2.8%) (Table 4). 1 before and after taking the same group for 2 years (1994 is the same period as 1995)
Even at the change in the record of 000 m, in 1995, taking n-3 fatty acids averaged -1 compared to 1994.
A reduction of 4 seconds was shown (Table 5, FIG. 2). Such 10,
In considering the background of the shortening of the 000 m record, assuming that almost the same training was conducted for two years, n-3 supplementary intake was added to the subject's endurance ability in addition to the training effect. The effectiveness of fatty acids was suggested. As the effectiveness of n-3 fatty acids, it has been reported that the blood flow of intramuscular capillaries is increased, and the peripheral oxygen supply due to the increase in fibrinolytic ability and erythrocyte deformability is reported. Any of these is considered to be an effect expected to improve various functions related to aerobic exercise ability, and it is presumed that a similar effect appears in the subject of this example. As a result, the year of taking n-3 fatty acid and the year of not taking it,
It appeared that there was a significant difference in shortening the 000 m record. Generally, it is said that the effect of training appears more remarkably in the early stage after the start of professional training, and the effect decreases as time passes. Competition level (record)
Similarly, the lower the period, the higher the recording improvement rate.
From this point, it is considered that the improvement in the record seen in this experiment targeting high-level active athletes is a unique change. From the above, it was suggested that taking the n-3 fatty acid for a certain period of time is effective as an auxiliary means for enhancing the aerobic capacity and improving the competitiveness of long-distance running.

【0020】[0020]

【表2】 [Table 2]

【0021】[0021]

【表3】 [Table 3]

【0022】[0022]

【表4】 [Table 4]

【0023】[0023]

【表5】 [Table 5]

【0024】実施例2 《運動時の血液レオロジーの変化に対する作用》 1.服用量・使用製剤 1)EPAとして1.6g/日を目途に摂取する。 2)EPA28%,DHA12%含有精製魚油カプセル
300mg×18粒/日を朝晩食直後9粒ずつ服用す
る。 2.被験者数 1)1群6名×2群〔EPA投与群(Fish)、EPA非投
与群(non-fish)〕 3.試験方法 1)表6に示すスケジュールで高地トレーニングに入る
10週間前より高地トレーニング終了時までEPA投与
群は精製魚油カプセルを18粒/日摂取する。 2)各群とも、投与開始時、高地トレーニング開始時、
高地トレーニング終了時に次項に述べる項目につき測定
する。
Example 2 << Effect on Changes in Blood Rheology During Exercise >> Dosage / use formulation 1) 1.6 g / day of EPA is ingested. 2) Take refined fish oil capsules containing 28% EPA and 12% DHA, 300 mg x 18 tablets / day, 9 tablets immediately after meal in the morning and evening. 2. 2. Number of test subjects 1) 6 groups per group x 2 groups [EPA administration group (Fish), EPA non-administration group (non-fish)] Test Method 1) The EPA administration group ingests 18 refined fish oil capsules / day from 10 weeks before entering high altitude training to the end of high altitude training according to the schedule shown in Table 6. 2) In each group, at the start of administration, at the start of high altitude training,
At the end of the high altitude training, the following items shall be measured.

【0025】[0025]

【表6】 [Table 6]

【0026】4.測定項目 1)生化学的項目 測定項目 (a)脂肪酸組成(血漿、赤血球膜リン脂質) (b)赤血球変形能 (c)降伏値 (d)アミノ酸組成 2)生理学的項目(運動能力) (1)測定項目 (a)最大酸素摂取量 (b)MSS(Maximal Steady Sta
te)測定:EPA投与・非投与群における持久性の変
化及び改善を検討。各トレーニングの前後に安静時の血
液を採取し、上述した項目について分析を行う。各トレ
ーニングの前後に2種類のスピードでの走行後、血中乳
酸濃度を測定し、4mmol/lに相当する走行スピー
ドを求める(MSS)。このMSSを指標に持久性の改
善を検討する。
4. Measurement items 1) Biochemical items Measurement items (a) Fatty acid composition (plasma, erythrocyte membrane phospholipid) (b) Erythrocyte deformability (c) Yield value (d) Amino acid composition 2) Physiological item (exercise ability) (1) ) Measurement items (a) Maximum oxygen uptake (b) MSS (Maximum Steady Sta
te) Measurement: Change and improvement of endurance in the EPA administration / non-administration group were examined. Blood at rest is collected before and after each workout and analyzed for the items described above. After running at two different speeds before and after each training, the blood lactate concentration is measured to determine a running speed equivalent to 4 mmol / l (MSS). Using this MSS as an index, we will consider improving endurance.

【0027】《結果》図3〜図8および表7〜表8に示
すように、魚油摂取群、非摂取群共にヘマトクリット値
には変化が認められなかったが、魚油摂取群で赤血球変
形能の有意な上昇が認められ、魚油非摂取群に認められ
た全血粘度の上昇は魚油摂取群では認められなかった。
<< Results >> As shown in FIGS. 3 to 8 and Tables 7 to 8, no change was observed in the hematocrit value of the fish oil intake group and the non-intake group, but the erythrocyte deformability of the fish oil intake group was low. A significant increase was observed, and the increase in whole blood viscosity observed in the fish oil non-administration group was not observed in the fish oil intake group.

【0028】[0028]

【表7】 [Table 7]

【0029】[0029]

【表8】 [Table 8]

【0030】[0030]

【発明の効果】健常人(スポーツ愛好家、スポーツをし
たい人、持久力の向上を目指す人など)のための運動能
力を高める食品を提供することができる。スポーツ選手
のための有酸素能力を高め、長距離走の競技力向上の補
助的な手段として有効である運動能力向上栄養食品を提
供することができる。
According to the present invention, it is possible to provide a food that enhances athletic ability for healthy people (sports enthusiasts, those who want to play sports, those who aim to improve endurance, etc.). It is possible to provide an athletic ability-enhancing nutritional food which is effective as an auxiliary means for enhancing aerobic ability for athletes and improving athletic ability for long-distance running.

【図面の簡単な説明】[Brief description of the drawings]

【図1】チーム全体の2年間のn−3脂肪酸の服用前後
(1994年は1995年と同時期)の10,000m
の記録の変化を示した図面である。
FIG. 1. 10,000 m before and after taking n-3 fatty acids for the entire team for 2 years (1994 is the same period as 1995).
3 is a diagram showing a change in the record of the present invention.

【図2】同一グループの2年間のn−3脂肪酸の服用前
後(1994年は1995年と同時期)の10,000
mの平均記録の変化を示した図面である。
FIG. 2: 10,000 before and after taking n-3 fatty acids in the same group for 2 years (1994 is the same period as 1995)
6 is a diagram showing a change in average recording of m.

【図3】健常人におけるEPA含有精製魚油10週間投
与の赤血球変形能の変化を示した図面である。
FIG. 3 is a graph showing changes in erythrocyte deformability in healthy subjects after administration of EPA-containing purified fish oil for 10 weeks.

【図4】健常人におけるEPA含有精製魚油10週間投
与の降伏値〔(回転高) shear rate 375sec-1〕の変化を
示した図面である。
FIG. 4 is a drawing showing changes in the yield value [(rotational height) shear rate 375 sec −1 ] of healthy fish after administration of EPA-containing purified fish oil for 10 weeks.

【図5】健常人におけるEPA含有精製魚油10週間投
与の降伏値〔(回転低) shear rate 37.5sec-1〕の変化
を示した図面である。
FIG. 5 is a graph showing changes in the yield value [(low rotation) shear rate 37.5 sec −1 ] of healthy fish after administration of EPA-containing purified fish oil for 10 weeks.

【図6】健常人におけるEPA含有精製魚油10週間投
与のヘマロクリット値の変化を示した図面である。
FIG. 6 is a graph showing changes in the hematocrit value of healthy fish after administration of EPA-containing purified fish oil for 10 weeks.

【図7】魚油摂取群の赤血球脂肪酸組成の変化を示した
図面である。
FIG. 7 is a drawing showing changes in the erythrocyte fatty acid composition of the fish oil intake group.

【図8】対照群の赤血球脂肪酸組成の変化を示した図面
である。
FIG. 8 is a graph showing a change in erythrocyte fatty acid composition of a control group.

Claims (7)

【特許請求の範囲】[Claims] 【請求項1】 n−3系高度不飽和脂肪酸を含有し、最
大酸素摂取量及び無気的閾値を少なくとも3%向上する
機能を有することを特徴とする健常人が運動能力を高め
る食品。
1. A food product which contains n-3 polyunsaturated fatty acids and has a function of improving maximal oxygen uptake and an anaerobic threshold value by at least 3%.
【請求項2】 n−3系高度不飽和脂肪酸が、n−3高
度不飽和脂肪酸または/およびその誘導体である請求項
1の健常人が運動能力を高める食品。
2. The food according to claim 1, wherein the n-3 polyunsaturated fatty acid is an n-3 polyunsaturated fatty acid and / or a derivative thereof.
【請求項3】 n−3系高度不飽和脂肪酸が、エイコサ
ペンタエン酸およびまたはドコサヘキサエン酸である請
求項1または2の健常人が運動能力を高める食品。
3. The food according to claim 1, wherein the n-3 polyunsaturated fatty acid is eicosapentaenoic acid and / or docosahexaenoic acid.
【請求項4】 n−3系高度不飽和脂肪酸が、天然のト
リグリセライドの形態である請求項1、2または3の健
常人が運動能力を高める食品。
4. The food according to claim 1, 2 or 3, wherein the n-3 polyunsaturated fatty acid is in the form of a natural triglyceride.
【請求項5】 n−3系高度不飽和脂肪酸が、魚油であ
る請求項4の運動時の危険因子除去能を有する組成物。
5. The composition according to claim 4, wherein the n-3 polyunsaturated fatty acid is fish oil.
【請求項6】 液状または固形である請求項1ないし5
のいずれかの健常人が運動能力を高める食品。
6. A liquid or a solid liquid.
Foods that increase the athletic ability of any healthy person.
【請求項7】 カプセルに入っている請求項6の健常人
が運動能力を高める食品。
7. The food according to claim 6, which is contained in a capsule and enhances athletic ability.
JP10168132A 1997-06-16 1998-06-16 Food product for healthy persons to increase their moving ability Pending JPH11239465A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10168132A JPH11239465A (en) 1997-06-16 1998-06-16 Food product for healthy persons to increase their moving ability

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP15821897 1997-06-16
JP36797997 1997-12-27
JP9-367979 1997-12-27
JP9-158218 1997-12-27
JP10168132A JPH11239465A (en) 1997-06-16 1998-06-16 Food product for healthy persons to increase their moving ability

Publications (1)

Publication Number Publication Date
JPH11239465A true JPH11239465A (en) 1999-09-07

Family

ID=27321309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10168132A Pending JPH11239465A (en) 1997-06-16 1998-06-16 Food product for healthy persons to increase their moving ability

Country Status (1)

Country Link
JP (1) JPH11239465A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009523414A (en) * 2005-12-21 2009-06-25 ブルーディ、テクノロジー、ソシエダッド、リミターダ Use of DHA, EPA or DHA-derived EPA to treat lesions associated with oxidative damage of cells
JP2014028830A (en) * 2005-12-21 2014-02-13 Brudy Technology Sl Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage
US9724318B2 (en) 2001-04-24 2017-08-08 Taiyo Kagaku Co., Ltd. Compositions for improving mental concentration
WO2024009986A1 (en) * 2022-07-04 2024-01-11 株式会社ニッスイ Endurance-improving agent

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9724318B2 (en) 2001-04-24 2017-08-08 Taiyo Kagaku Co., Ltd. Compositions for improving mental concentration
JP2009523414A (en) * 2005-12-21 2009-06-25 ブルーディ、テクノロジー、ソシエダッド、リミターダ Use of DHA, EPA or DHA-derived EPA to treat lesions associated with oxidative damage of cells
KR101256448B1 (en) * 2005-12-21 2013-04-19 브루디 테크놀로지 에스엘 Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
JP2014028830A (en) * 2005-12-21 2014-02-13 Brudy Technology Sl Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage
JP2015157838A (en) * 2005-12-21 2015-09-03 ブルーディ、テクノロジー、ソシエダッド、リミターダBrudy Technology,S.L. Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage
JP2016128494A (en) * 2005-12-21 2016-07-14 ブルーディ、テクノロジー、ソシエダッド、リミターダBrudy Technology,S.L. Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage
JP2017095496A (en) * 2005-12-21 2017-06-01 ブルーディ、テクノロジー、ソシエダッド、リミターダBrudy Technology,S.L. Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage
WO2024009986A1 (en) * 2022-07-04 2024-01-11 株式会社ニッスイ Endurance-improving agent

Similar Documents

Publication Publication Date Title
CA2147302C (en) A lipid composition for normalizing injury
KR20050040127A (en) Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
CN101720822A (en) Nutritional blend oil with balanced fatty acid component and active component for middle and old aged
Tamura et al. Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan
JP2008035714A (en) Health food
CN108669540A (en) Cerebral apoplexy tailored version clinical nutrition formula and preparation method thereof
JP2009107954A (en) Stamina-enhancing agent, food for enhancing stamina and pharmaceutical for enhancing stamina
US20090130219A1 (en) Composition for Improving Lipid Metabolism
EP1004303B1 (en) Composition having capability of removing risk factor during exercise
JP5547486B2 (en) Composition containing sesamin and arachidonic acid
JPH11239465A (en) Food product for healthy persons to increase their moving ability
US20070082063A1 (en) Risk assessment and correction of membrane damage of the upper GI tract
JP6180485B2 (en) Oil compositions, formulations containing oil compositions, and their use to prevent or treat obesity-related diseases and disorders by reducing the accumulation of built-in fats and improving glucose tolerance
JPS6336744A (en) Edible oil and fat composition effective in preventing allergy, thrombosis and hypertension
JP5794761B2 (en) Anti-fatigue agent containing sesamin and vitamin E
Pham-Huy et al. Food and Lifestyle in Health and Disease
CN1679593A (en) Composite preparation containing alpha-linolenic acid free acid, soybean phospholipid and vitamin E
JPH11239464A (en) Composition having activity to remove risk factor during exercise
RU2752298C1 (en) Biologically active dietary supplement for normalising lipid metabolism and method for application thereof
Gligor et al. The potential role of omega-3 fatty acids supplements in increasing athletic performance
WO2024009986A1 (en) Endurance-improving agent
JP2000302677A (en) Medicine and food/feed composition having improving action on carnitine self production ability
FR2911252A1 (en) Composition, useful for slowing the aging process of organism, comprises two vegetable oils, rich in monounsaturated fatty acids and omega acid, a marine oil rich in omega, lycopene and vitamin E
Tajik Serum long-chain omega-3 polyunsaturated fatty acids, methylmercury and cardiac functions: a population-based cohort
ES2925125A1 (en) Food and functional use of Ocimum basilicum seed oil (Machine-translation by Google Translate, not legally binding)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050615

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20060901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061215

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070315